Kenfarb & Co’s Gilead Sciences GILD Stock Holding History

Kenfarb & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$6K	–	230
2022 Q3	$6K	Buy	+100	New	+$6.31K	0.01%	200

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kenfarb & Co's GILD Position: Q4 2022 in Review

Kenfarb & Co sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 100 shares — an estimated $6K sold.

Kenfarb & Co first reported a position in GILD in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

Kenfarb & Co reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
Kenfarb & Co sold 100 Gilead Sciences shares in Q4 2022, an estimated $6K.
Kenfarb & Co first reported a position in Gilead Sciences in Q3 2022 and held it in 1 quarter.
Kenfarb & Co's Gilead Sciences position peaked at $6K in Q3 2022.
1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Kenfarb & Co's 13F filing for Q4 2022, filed 14 Feb 2023.